Tech Company Financing Transactions
Fortis Therapeutics Funding Round
Avalon Ventures, Lilly Asia Ventures and Osage Partners invested in a $18 million Series A venture round for Fortis Therapeutics. The financing closed on 9/28/2016.
Transaction Overview
Company Name
Announced On
9/28/2016
Transaction Type
Venture Equity
Amount
$18,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
11099 North Torrey Pines Rd. 290
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Website
Email Address
Not Recorded
Overview
Fortis Therapeutics is an immuno-oncology biotech focused on developing new antibody drug conjugate therapies against CD46 for the treatment of late-stage multiple myeloma and late-stage prostate cancer and other indications. Fortis was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jay Lichter
Chief Financial Officer
Tighe Reardon
Chief Medical Officer
Andrew Dorr
Chief Scientific Officer
Marc Nasoff
VP - Bus. Development
Leonard Post
Browse more venture capital transactions:
Prev: 9/28/2016: DeepGram venture capital transaction
Next: 9/29/2016: Contrast Security venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs